 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...120121122123124125126127128129130...132133» |
- metformin / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment open, Metastases: A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Oct 7, 2013
P2, N=64, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting
- temozolomide / Generic mfg., everolimus / Generic mfg.
Enrollment closed: Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Oct 7, 2013
P1/2, N=246, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Simulect (basiliximab) / Novartis
Clinical: TRANSFORMt: Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) (clinicaltrials.gov) - Sep 24, 2013
P4, N=2040, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| everolimus / Generic mfg.
New P4 trial: INPRES: Influence of Exceptional Patient Characteristics on Everolimus Exposure (clinicaltrials.gov) - Sep 22, 2013
P4, N=75, Recruiting, Sponsor: Radboud University
- |||||| everolimus / Generic mfg., exemestane / Generic mfg.
Enrollment open, Metastases: Evelyn: Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane (clinicaltrials.gov) - Sep 19, 2013
P3, N=134, Recruiting, Sponsor: German Breast Group
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- |||| everolimus / Generic mfg.
Enrollment open: INPRES: Influence of Exceptional Patient Characteristics on Everolimus Exposure (clinicaltrials.gov) - Sep 18, 2013
P4, N=75, Recruiting, Sponsor: Radboud University
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- | everolimus / Generic mfg.
Trial completion: Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) (clinicaltrials.gov) - Sep 16, 2013
P1/2, N=20, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Kisqali (ribociclib) / Novartis
Enrollment open, Combination therapy, Metastases: Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Sep 16, 2013
P1/2, N=185, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Enrollment change: Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients (clinicaltrials.gov) - Sep 13, 2013
P3, N=266, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=470 --> 266
- ||||||| Trial completion: Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients (clinicaltrials.gov) - Sep 13, 2013
P3, N=266, Completed, Sponsor: Novartis Pharmaceuticals
N=470 --> 266 Recruiting --> Completed
- | cisplatin / Generic mfg., everolimus / Generic mfg., gemcitabine / Generic mfg.
New P2 trial, Metastases: Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer (clinicaltrials.gov) - Sep 9, 2013
P2, N=116, Recruiting, Sponsor: National Cancer Center, Korea
- | everolimus / Generic mfg.
New P2 trial: A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis (clinicaltrials.gov) - Sep 4, 2013
P2, N=48, Recruiting, Sponsor: Cardiff University
- | Simulect (basiliximab) / Novartis
Trial completion, Combination therapy: Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study) (clinicaltrials.gov) - Sep 4, 2013
P2, N=16, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment closed, P2 data, Metastases: EVERLAR: Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET (clinicaltrials.gov) - Sep 3, 2013
P2, N=40, Active, not recruiting, Sponsor: Grupo Espanol de Tumores Neuroendocrinos
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Campath (alemtuzumab) / Sanofi
New P4 trial: Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath (clinicaltrials.gov) - Sep 2, 2013
P4, N=50, Recruiting, Sponsor: University of Toledo Health Science Campus
- | everolimus / Generic mfg.
Enrollment change, Metastases: An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) (clinicaltrials.gov) - Aug 28, 2013
P4, N=15, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=40 --> 15
- | everolimus / Generic mfg.
Enrollment closed, Metastases: An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) (clinicaltrials.gov) - Aug 28, 2013
P4, N=15, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=40 --> 15 Recruiting --> Active, not recruiting
- everolimus / Generic mfg., sirolimus / Generic mfg.
Enrollment open: RAPT: Rapalogues for Autism Phenotype in TSC: A Feasibility Study (clinicaltrials.gov) - Aug 27, 2013
P2, N=3, Recruiting, Sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- cisplatin / Generic mfg., everolimus / Generic mfg.
New P2 trial: NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer (clinicaltrials.gov) - Aug 27, 2013
P2, N=32, Recruiting, Sponsor: The Methodist Hospital System
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment change: Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. (clinicaltrials.gov) - Aug 26, 2013
P4, N=31, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=17 --> 31
- everolimus / Generic mfg., sorafenib / Generic mfg.
Enrollment open: EVESOR: a Phase 1 Trial of Everolimus and Sorafenib (clinicaltrials.gov) - Aug 26, 2013
P1, N=60, Recruiting, Sponsor: Hospices Civils de Lyon
N=17 --> 31 Not yet recruiting --> Recruiting
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment open: Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. (clinicaltrials.gov) - Aug 26, 2013
P4, N=31, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- cisplatin / Generic mfg., everolimus / Generic mfg.
Enrollment open: NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer (clinicaltrials.gov) - Aug 25, 2013
P2, N=32, Recruiting, Sponsor: The Methodist Hospital System
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Enrollment closed, Combination therapy, Metastases: Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Aug 22, 2013
P4, N=73, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
Trial completion: PIGREC: Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients (clinicaltrials.gov) - Aug 22, 2013
P4, N=42, Completed, Sponsor: University Hospital, Limoges
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||||| everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
Enrollment open: Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients (clinicaltrials.gov) - Aug 21, 2013
P3, N=106, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Recruiting
- Herceptin (trastuzumab) / Roche
Trial initiation date, Metastases: Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis (clinicaltrials.gov) - Aug 21, 2013
P1/2, N=47, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Active, not recruiting --> Recruiting Initiation date: Feb 2013 --> Jun 2013
- Herceptin (trastuzumab) / Roche
Enrollment open, Metastases: Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis (clinicaltrials.gov) - Aug 21, 2013
P1/2, N=47, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Initiation date: Feb 2013 --> Jun 2013 Not yet recruiting --> Recruiting
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Combination therapy, Metastases: A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment (clinicaltrials.gov) - Aug 21, 2013
P1/2, N=180, Active, not recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- everolimus / Generic mfg., mycophenolate sodium / Generic mfg.
New P4 trial: Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients (clinicaltrials.gov) - Aug 20, 2013
P4, N=50, Not yet recruiting, Sponsor: Fundação Pró Rim
- ||||| everolimus / Generic mfg., exemestane / Generic mfg.
Enrollment closed, HEOR, Combination therapy, Metastases: MACS2096: 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Aug 19, 2013
P3, N=302, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- everolimus / Generic mfg., docetaxel / Generic mfg.
Trial termination, Metastases: Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 18, 2013
P1/2, N=28, Terminated, Sponsor: Emory University
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; data analysis showed insufficient drug efficacy
- Trial completion, Metastases: Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer (clinicaltrials.gov) - Aug 18, 2013
P2, N=40, Completed, Sponsor: National Taiwan University Hospital
Active, not recruiting --> Terminated; data analysis showed insufficient drug efficacy Active, not recruiting --> Completed
- everolimus / Generic mfg.
Biomarker, Enrollment closed, Metastases: Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Aug 15, 2013
P2, N=40, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| everolimus / Generic mfg., cyclosporine / Generic mfg.
Trial initiation date, Combination therapy: Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. (clinicaltrials.gov) - Aug 14, 2013
P3, N=75, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Initiation date: Jul 2012 --> Oct 2012
- ||||| everolimus / Generic mfg., cyclosporine / Generic mfg.
Enrollment change, Combination therapy: Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. (clinicaltrials.gov) - Aug 14, 2013
P3, N=75, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Jul 2012 --> Oct 2012 N=175 --> 75
- |||||| everolimus / Generic mfg., cyclosporine / Generic mfg.
Enrollment open, Combination therapy: Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. (clinicaltrials.gov) - Aug 14, 2013
P3, N=75, Recruiting, Sponsor: Novartis Pharmaceuticals
N=175 --> 75 Not yet recruiting --> Recruiting
- everolimus / Generic mfg., sorafenib / Generic mfg.
Trial completion, Metastases: Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer (clinicaltrials.gov) - Aug 14, 2013
P1/2, N=78, Completed, Sponsor: SCRI Development Innovations, LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| everolimus / Generic mfg., exemestane / Generic mfg.
Trial initiation date, Metastases: Evelyn: Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane (clinicaltrials.gov) - Aug 12, 2013
P3, N=134, Recruiting, Sponsor: German Breast Group
Active, not recruiting --> Completed Initiation date: Apr 2013 --> Jul 2013
- everolimus / Generic mfg., sirolimus / Generic mfg.
New P2 trial: RAPT: Rapalogues for Autism Phenotype in TSC: A Feasibility Study (clinicaltrials.gov) - Aug 6, 2013
P2, N=3, Recruiting, Sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- | cisplatin / Generic mfg., everolimus / Generic mfg., docetaxel / Generic mfg.
Trial completion, Metastases: RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer (clinicaltrials.gov) - Aug 6, 2013
P1, N=18, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Initiation date: Apr 2013 --> Jul 2013 Active, not recruiting --> Completed
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., everolimus / Generic mfg.
Enrollment change, Metastases: Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer (clinicaltrials.gov) - Jul 23, 2013
P1/2, N=44, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed N=26 --> 44
- cisplatin / Generic mfg., everolimus / Generic mfg.
Enrollment change, IO biomarker: Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer (clinicaltrials.gov) - Jul 22, 2013
P1, N=13, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=26 --> 44 N=42 --> 13
- | cisplatin / Generic mfg., everolimus / Generic mfg.
Trial completion, IO biomarker: Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer (clinicaltrials.gov) - Jul 22, 2013
P1, N=13, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=42 --> 13 Active, not recruiting --> Completed
- linsitinib (ASP7487) / Sling Therap
Trial completion, Metastases: Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 18, 2013
P1, N=18, Completed, Sponsor: SCRI Development Innovations, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial completion, Metastases: Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma (clinicaltrials.gov) - Jul 17, 2013
P2, N=80, Completed, Sponsor: SCRI Development Innovations, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | everolimus / Generic mfg.
Enrollment change: RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM (clinicaltrials.gov) - Jul 14, 2013
P1/2, N=36, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Active, not recruiting --> Completed N=30 --> 36
- | everolimus / Generic mfg.
Trial completion: RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM (clinicaltrials.gov) - Jul 14, 2013
P1/2, N=36, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
N=30 --> 36 Active, not recruiting --> Completed
- ||||||| Simulect (basiliximab) / Novartis
Trial completion: Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy (clinicaltrials.gov) - Jul 11, 2013
P3, N=200, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
New P4 trial: Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria (clinicaltrials.gov) - Jul 8, 2013
P4, N=200, Not yet recruiting, Sponsor: Helio Tedesco Silva Junior